XX US Sales: Despite McNeil business de-growth, sequential improvement is largely due to ramp-up in own and acquired products. Overall price erosion is lower compared to Q1FY17. Recently acquired Teva's products are under patent litigation. Management expect to launch gGleevec in Q4FY17 (site transfer already done). Validation for gCopaxone has been completed and plans to submit its DMF next month. Aloxi litigation...